TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603)
[177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial
A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC)
Large varieties in the use and uptake of active surveillance for low risk prostate cancer between an academic center and the remaining urology community in the canton of Zurich, Switzerland
3-year outcomes from the prospective ‘MRIAS’ trial: A novel active surveillance protocol which incorporates multiparametric MRI to reduce frequency of biopsy in men with prostate cancer
Individualized risk prediction of metastatic recurrence in patients candidate to radical prostatectomy: A new model using clinical, mri and mri-guided biopsy parameters
Pre-surgery blood levels of leucine-rich alpha-2-glycoprotein 1 identify patients with a high risk of progressing to castration-resistant prostate cancer
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial